Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients.

Shi Y, Li M, Song C, Xu Q, Huo R, Shen L, Xing Q, Cui D, Li W, Zhao J, He L, Qin S.

Transl Psychiatry. 2017 Jul 11;7(7):e1170. doi: 10.1038/tp.2017.143.

2.

Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method.

Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, Geddes J, Davis JM.

Schizophr Bull. 2015 Nov;41(6):1397-402. doi: 10.1093/schbul/sbv037. Epub 2015 Apr 3. Review.

3.

A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia.

Shoja Shafti S, Gilanipoor M.

Schizophr Res Treatment. 2014;2014:307202. doi: 10.1155/2014/307202. Epub 2014 Aug 26.

4.

Psychotic disorders in children and adolescents: a primer on contemporary evaluation and management.

Stevens JR, Prince JB, Prager LM, Stern TA.

Prim Care Companion CNS Disord. 2014;16(2). pii: PCC.13f01514. doi: 10.4088/PCC.13f01514. Epub 2014 Mar 13. No abstract available.

5.

Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis.

Ansell BR, Dwyer DB, Wood SJ, Bora E, Brewer WJ, Proffitt TM, Velakoulis D, McGorry PD, Pantelis C.

Psychol Med. 2015 Feb;45(3):515-27. doi: 10.1017/S0033291714001652. Epub 2014 Jul 31.

6.

Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics.

Wakamatsu A, Aoki K, Sakiyama Y, Ohnishi T, Sugita M.

Innov Clin Neurosci. 2013 Mar;10(3):23-30.

7.

Frequency dependent alterations in regional homogeneity of baseline brain activity in schizophrenia.

Yu R, Hsieh MH, Wang HL, Liu CM, Liu CC, Hwang TJ, Chien YL, Hwu HG, Tseng WY.

PLoS One. 2013;8(3):e57516. doi: 10.1371/journal.pone.0057516. Epub 2013 Mar 6.

8.

Factors that influence the prescription of antipsychotics for patients with schizophrenia in china.

Si TM, Shu L, Li KQ, Liu XH, Mei QY, Wang GH, Bai PS, Ji LP, Chen XS, Ma C, Shi JG, Zhang HY, Ma H, Yu X.

Clin Psychopharmacol Neurosci. 2011 Dec;9(3):122-8. doi: 10.9758/cpn.2011.9.3.122. Epub 2011 Dec 31.

9.

When to hold that thought: an experimental study showing reduced inhibition of pre-trained associations in schizophrenia.

He Z, Cassaday HJ, Park SB, Bonardi C.

PLoS One. 2012;7(7):e42175. doi: 10.1371/journal.pone.0042175. Epub 2012 Jul 30.

10.

Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population.

Huo R, Tang K, Wei Z, Shen L, Xiong Y, Wu X, Niu J, Han X, Tian Z, Yang L, Feng G, He L, Qin S.

PLoS One. 2012;7(5):e34809. doi: 10.1371/journal.pone.0034809. Epub 2012 May 11.

11.

Dendritic spine pathology in schizophrenia.

Glausier JR, Lewis DA.

Neuroscience. 2013 Oct 22;251:90-107. doi: 10.1016/j.neuroscience.2012.04.044. Epub 2012 Apr 27. Review.

12.

Treatment-refractory schizophrenia.

Caspi A, Davidson M, Tamminga CA.

Dialogues Clin Neurosci. 2004 Mar;6(1):61-70.

13.

Comparative effectiveness of antipsychotic drugs in schizophrenia.

Stroup TS, A Lieberman J, S Swartz M, McEvoy JP.

Dialogues Clin Neurosci. 2000 Dec;2(4):373-9.

14.

Deltoid injections of risperidone long-acting injectable in patients with schizophrenia.

Quiroz JA, Rusch S, Thyssen A, Palumbo JM, Kushner S.

Innov Clin Neurosci. 2011 Jun;8(6):20-8.

15.

Past and present progress in the pharmacologic treatment of schizophrenia.

Kane JM, Correll CU.

J Clin Psychiatry. 2010 Sep;71(9):1115-24. doi: 10.4088/JCP.10r06264yel. Review.

16.

Anticholinergic use in children and adolescents after initiation of antipsychotic therapy.

Hong IS, Bishop JR.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1171-80. doi: 10.1345/aph.1M643. Epub 2010 Jun 29.

17.

Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.

Peuskens J, Trivedi J, Malyarov S, Brecher M, Svensson O, Miller F, Persson I, Meulien D.

Psychiatry (Edgmont). 2007 Nov;4(11):34-50.

18.

Study of cenesthesias and body image aberration in schizophrenia.

Rajender G, Kanwal K, Rathore DM, Chaudhary D.

Indian J Psychiatry. 2009 Jul-Sep;51(3):195-8. doi: 10.4103/0019-5545.55086.

19.

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia.

Ren XS, Herz L, Qian S, Smith E, Kazis LE.

Neuropsychiatr Dis Treat. 2009;5:491-8. Epub 2009 Oct 12.

20.

A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy.

Lasser RA, Schooler NR, Kujawa M, Docherty J, Weiden P.

Psychiatry (Edgmont). 2009 Apr;6(4):22-7.

Supplemental Content

Support Center